Sino Biological, Inc., one of the most renowned international leaders in the field of recombinant technology, has formally launched its innovative XPressMAX™ Cell-Free Protein Synthesis Kit. The novel solution is designed specifically to facilitate the high-throughput screening pipeline that utilizes artificial intelligence (AI) for the discovery of antibodies of the future generation.
The recently launched kit is based on state-of-the-art cell-free protein synthesis technology that ensures extremely fast and efficient in vitro synthesis of target proteins and antibodies. Being devoid of the limitations inherent in cell-based expression systems, the technology can be easily combined with AI-driven screening technologies to facilitate evaluation, selection, and optimization of antibodies at a much faster pace with significantly reduced development expenses.
Also Read: OpenAI Unveils GPT-Rosalind: A Frontier Reasoning Model Tailored for Life Sciences
Utilizing an E. coli lysate core supplemented with vital transcription and translation components, XPressMAX™ facilitates direct protein synthesis from either PCR or plasmid templates. Purpose-built to meet the demands of modern antibody drug discovery, the kit supports the rapid expression and validation of VHH, scFv, Fab, and Miniproteins. By incorporating the XPressMAX™ infrastructure, Sino Biological has successfully established a high-throughput, cell-free platform capable of validating more than 2,000 scFv/VHH molecules within a three-to-four-week window matching the rapid iteration cycles required by modern AI models.
Key Performance Highlights of XPressMAX™:
- Ultra-Rapid Workflows: Complete protein synthesis achieved in as little as 3 hours.
- Exceptional Reliability: Demonstrates a proven success rate exceeding 99%.
- Advanced Structural Folding: Supports complex disulfide bonds, enabling native folding and robust bioactivity without requiring external enhancers.
“XPressMAX™ represents a significant advancement in next-generation therapeutic discovery tools and reagents,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid and reliable protein expression with intelligent screening, we are helping our partners dramatically reduce time to antibody discovery without compromising quality.”
“AI is revolutionizing antibody screening, but it requires expression systems that can keep pace with its speed and throughput,” said Dr. Jie Zhang, General Manager of Sino Biological. “XPressMAX™ enables the rapid and highly successful expression of challenging proteins in just 3 hours.”
